GIS:FRA
Gilead Sciences, Inc
155,24 €
arrow_upward
+0,01%(+0,020) 1 D
17. nov., 15:58:19 GMT+1 · EUR
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for GIS …
Åpne
151,84 €
Høy
155,24 €
Lav
151,84 €
Markedsverdi
210,07 mrd.
Snittvolum
224,00
Volum
643,00
52 u høy
157,14 €
52 u lav
100,42 €
Antall ansatte
17k
Åpne
151,84 €
Høy
155,24 €
Lav
151,84 €
Markedsverdi
210,07 mrd.
Snittvolum
224,00
Volum
643,00
52 u høy
157,14 €
52 u lav
100,42 €
Antall ansatte
17k
Nyhetssaker
Fra nettkilder og nyhetspartnere
Investing.com
·
for 9 minutter siden
Gilead at Jefferies Global Healthcare Conference: growth broadens
Pharmaceutical Executive
·
for 1 time siden
Gilead Signs Royalty-Free Licensing Deals to Broaden Access to Obeldesivir
Yahoo Finance
·
for 1 time siden
Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035
Yahoo Finance
·
for 2 timer siden
Gilead Sciences Bets on HIV Prevention Growth Despite $1.5 Billion Biktarvy Headwind
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Om Gilead Sciences, Inc
Administrerende direktørDaniel O'Day
Ansatte17k
Grunnlagt22. juni 1987
HovedkontorFoster City, California, USA
SektorHealth Care
Bransje-
Nettstedgilead.com